Lipoprotein-associated phospholipase A2 (Lp-PLA2) can be used to evaluate risk in statin-naïve patients for primary prevention and may be helpful as a complementary marker of risk alongside high-sensitivity C-reactive protein (hs-CRP), but it is not designed as a goal of therapy or for risk prediction in secondary prevention.

Authors

• Person: Not available Organization: National Lipid Association
  EBM Tools for Practice: Best Biomarkers for Inflammation

Sources

• EBM Tools for Practice: Best Biomarkers for Inflammation www.lipid.org National Lipid Association via serper

Referenced by nodes (1)

• high-sensitivity C-reactive protein concept